Rodolfo Savitzky to succeed Toralf Haag as Lonza Group CFO
Rodolfo Savitzky appointed as new CFO for Lonza Group to succeed Toralf Haag who was appointed as CFO of the Voith Group in Germany
Lonza today announced that its Board of Directors appointed Rodolfo Savitzky as new CFO for Lonza. In this function he will be succeeding Toralf Haag, who after 11 years of service for Lonza accepted an offer from the Voith Group in Germany to become their new CFO and member of the Corporate Board of Management. The change will be effective as of 1 October 2016, when Rodolfo Savitzky will also succeed Toralf Haag as a member of the Lonza Executive Committee.
Rodolfo Savitzky (54) joined Lonza in March 2015 as Head of Finance & Controlling for the Pharma&Biotech segment. Previously he was CFO for the Animal Health Division of Novartis. Prior to this position, Rodolfo Savitzky held various financial management positions with increasing responsibilities at Novartis and Procter & Gamble. He holds an MBA in Finance/Economics from the University of Chicago. With his broad financial and industry background, his thorough understanding of Lonza’s strategic direction and his contributions to the Pharma&Biotech segment, Rodolfo Savitzky brings the necessary skillset to his new position.
Toralf Haag joined Lonza in 2005 as CFO and since then successfully led the financial organization of Lonza. He was significantly involved in the strategic development of Lonza and managed M&A projects successfully, as well as refinancing projects and the deleveraging of the company.
“I would like to take this opportunity to express my sincere thanks to Toralf for the services he has provided to this company. He led the finance department vigilantly and managed to steer the financial activities of Lonza successfully also through difficult times. Today he can hand over a financially solid company with a healthy balance sheet,” said Lonza CEO Richard Ridinger. “With Rodolfo Savitzky we found an excellent internal solution; and with the handover in early October, we can benefit from a well-planned and thought-through handover process, in which Toralf will continue to support a number of important projects.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance